Laser and Retinal Research Unit, Department of Ophthalmology, King's College Hospital, London SE5 9RS, UK.
Ophthalmologica. 2013;230(1):27-33. doi: 10.1159/000350238. Epub 2013 Apr 30.
To assess the 3-year visual outcome and injection frequency for patients on ranibizumab for neovascular age-related macular degeneration (NV-AMD).
Retrospective case-note review of 174 treatment-naïve eyes of 156 patients with NV-AMD with 3-year follow-up was done at specific time points closest to 12, 24 and 36 months.
The median baseline visual acuity (VA) of 50 Early Treatment Diabetic Retinopathy Study letters (mean 48.2 ± 16.9) improved significantly to 55 (mean 51.2 ± 18.7) by the end of 12 months (p = 0.04). At 24 months, the median letter score remained unchanged at 55 (mean 50.4 ± 20.8; p = 0.14 as compared to baseline) and at 36 months, the median VA was 54 letters (mean 49.1 ± 21.7; p = 0.34 compared to baseline). The mean numbers of injections were 4.8 ± 2.2 at 1 year, 7.8 ± 4.2 at 2 years (2.9 in the second year) and 10.2 ± 6.2 at the end of the third year (2.4 in the third year).
Our study demonstrates the efficacy of a variable dosing regimen of ranibizumab for the treatment of NV-AMD. The mean gain in VA is inversely proportional to the baseline VA and did not correlate with the number of injections.
评估接受雷珠单抗治疗的新生血管性年龄相关性黄斑变性（NV-AMD）患者的 3 年视力结果和注射频率。
对 156 名 NV-AMD 患者的 174 只未经治疗的眼睛进行回顾性病历回顾，这些患者在特定时间点进行了 3 年随访，时间最接近 12、24 和 36 个月。
基线时视力（VA）中位数为 50 个早期治疗糖尿病视网膜病变研究字母（平均 48.2 ± 16.9），在 12 个月时显著提高到 55 个（平均 51.2 ± 18.7）（p = 0.04）。在 24 个月时，字母评分中位数保持不变，为 55 个（平均 50.4 ± 20.8；与基线相比，p = 0.14），在 36 个月时，VA 中位数为 54 个字母（平均 49.1 ± 21.7；与基线相比，p = 0.34）。第一年的平均注射次数为 4.8 ± 2.2，第二年为 7.8 ± 4.2（第二年为 2.9），第三年结束时为 10.2 ± 6.2（第三年为 2.4）。
我们的研究表明，雷珠单抗的可变剂量方案治疗新生血管性年龄相关性黄斑变性是有效的。VA 的平均增益与基线 VA 成反比，与注射次数无关。
